These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3576653)

  • 1. Pharmacodynamics of warfarin at steady state.
    Murray B; Coleman R; McWaters D; Ludden T; Mungall D
    Ther Drug Monit; 1987; 9(1):1-5. PubMed ID: 3576653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.
    Fuder H; Kleist P; Birkel M; Ehrlich A; Emeklibas S; Maslak W; Stridde E; Wetzelsberger N; Wieckhorst G; Lücker PW
    Eur J Clin Pharmacol; 1997; 53(2):153-7. PubMed ID: 9403289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship.
    Holford NH
    Clin Pharmacokinet; 1986; 11(6):483-504. PubMed ID: 3542339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of warfarin at steady state.
    Routledge PA; Chapman PH; Davies DM; Rawlins MD
    Br J Clin Pharmacol; 1979 Sep; 8(3):243-7. PubMed ID: 497091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin.
    Mangold B; Gielsdorf W; Marino MR
    Eur J Clin Pharmacol; 1999 Oct; 55(8):593-8. PubMed ID: 10541778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole potentiates warfarin-induced prothrombin time prolongation.
    Purkins L; Wood N; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):24-9. PubMed ID: 14616410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.
    Awni WM; Hussein Z; Granneman GR; Patterson KJ; Dubé LM; Cavanaugh JH
    Clin Pharmacokinet; 1995; 29 Suppl 2():67-76. PubMed ID: 8620673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomogram for dosing warfarin at steady state.
    Fredriks DA; Coleman RW
    Clin Pharm; 1991 Dec; 10(12):923-7. PubMed ID: 1773579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.
    Kong AN; Tomasko L; Waldman SA; Osborne B; Deutsch PJ; Goldberg MR; Bjornsson TD
    J Clin Pharmacol; 1995 Oct; 35(10):1008-15. PubMed ID: 8568008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: preliminary evaluation.
    Svec JM; Coleman RW; Mungall DR; Ludden TM
    Ther Drug Monit; 1985; 7(2):174-80. PubMed ID: 4024210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of cimetidine on the steady-state pharmacokinetics and pharmacodynamics of warfarin in humans.
    Niopas I; Toon S; Aarons L; Rowland M
    Eur J Clin Pharmacol; 1999 Jul; 55(5):399-404. PubMed ID: 10456491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the daily prothrombin time response to warfarin.
    Farrow L; Mungall D; Raskob G; Hull R
    Ther Drug Monit; 1990 May; 12(3):246-9. PubMed ID: 2349607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of using warfarin plasma concentrations in Bayesian forecasting of prothrombin-time response.
    Lee C; Coleman RW; Mungall DR
    Clin Pharm; 1987 May; 6(5):406-12. PubMed ID: 3665392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs.
    Shen C; Huang X; Li J; Zhang P; Li L; Zhang W; Hu T; Pappoe F; Huang J; Tang H
    Xenobiotica; 2016; 46(6):530-41. PubMed ID: 26548565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of Shuxuetong injection on anticoagulant effect of warfarin in rats].
    Zhao HF; Sun JH; Liu S; Liu Y; Liu GF
    Zhongguo Zhong Yao Za Zhi; 2017 Mar; 42(5):982-988. PubMed ID: 28994544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
    Dieterle W; Corynen S; Mann J
    Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.
    Chan E; McLachlan A; O'Reilly R; Rowland M
    Clin Pharmacol Ther; 1994 Sep; 56(3):286-94. PubMed ID: 7924124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats.
    Zhu M; Chan KW; Ng LS; Chang Q; Chang S; Li RC
    J Pharm Pharmacol; 1999 Feb; 51(2):175-80. PubMed ID: 10217316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between warfarin and propafenone in healthy volunteer subjects.
    Kates RE; Yee YG; Kirsten EB
    Clin Pharmacol Ther; 1987 Sep; 42(3):305-11. PubMed ID: 3621785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin.
    Toon S; Holt BL; Mullins FG; Bullingham R; Aarons L; Rowland M
    Br J Clin Pharmacol; 1990 Nov; 30(5):743-50. PubMed ID: 2271374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.